NOW you can visit the Useful_DOPE website!
This exciting new program publicaly disclosed the 26th of March, 2018 is now functioning in the U.S.A. ameliorating the 500 billion dollar annual loss caused by our Opiate Epidemic. Highly involved stake-holders can include local state doctors and departments for public health at a public university, with further aid from a computational and statistical model building team.
Considerations:
- The initial statistical requirements are regression analysis (R or STATA) based upon patient data combed from hospital charts. The complexity of the programming of AI and/or pipeline computational analysis can increase over time. However, any undergraduate or graduate student studying econometrics can establish the basis for the prediction algorithm and the basis for the English language patient chart data analysis.
- Furthermore, the initial usage of the ozone within joints can be offered to willing patients, so clinical data can be collected, analyzed, and established. This is basic clinical research, and there are very few risks with ozone joint injection; it has a low implementation and overall maintenance cost.
- Kratom and the FDA just made history yesterday, 3rd of April, 2018. They forced Triangle Pharmaceuticals to recall all of their kratom powders in the U.S.A., which has never occurred ex post an optional market recall request due to salmonella contamination. There is concern for quality control of kratom, and MEDRAR believes it should be studied before regulated within reasonable and limited extent for safety measure and drug-drug interactions. The window for clinical study of this plant is now, before there are too many legal barriers.
This fresh program is exciting and offers massive ROI via importation and safer control of kratom for valid safety and quality control and via importation, transference, and training with ozone equipment. The long-term impacts over 10+ years span inter-governmental software sharing platform MoU’s to the redefining of allopathic medical industry’s standard of care for patient chronic pain.
Program Directorship
Martin
iPROUD, Program Director
- Research available federal and local grants
- Design of clinical projects with respect to Kratom (plant medicine) as an alternative opioid detox tool, ozone joint injection as an alternative pain management therapy – matching study and project designs to funding opportunities in order to acquire resources in line with the iPROUD mission of integrative Program Response for Opiate Use Disorder
- Fiduciary of basic research and expansion into sales markets
- Oversee funded project(s) and clinical studies from start to finish, ensuring requirements of FDA quality are satisfied alongside Medrar’s mission, addressing any corporate considerations as member to Medrar’s IRB
- Collaborate with Outreach Director for any and all clinical research
- Product(s) formula IP and design principles alongside CEO
Gail
iPROUD, Outreach Director
- Sales outreach and online presence, social media
- Professional, personable face for company marketing events, lectures, dinners, and promotional materials
- Travel to groups at rehab centers, AA, addiction help groups, Community Bridges, shop owners (e.g. Trails, online groups, Lifewell), pain management related recovery support groups, methadone clinics, to contact participants for the studies
- Maricopa and Pima counties – relations with health departments
- Building narrative of product(s) demonstrating essence of iPROUD
- Relations of iPROUD Empowerment and Stigma reduction efforts – employees, partners, volunteers, and participants
- Document and record keeping and processing
- Develop personal clinical pitch and information on product(s) through networking, as tailored and informing what reaches future patient markets
- Communications on product definition based upon real-life community members’ accurate feedback
Please feel free to contact us with any questions.